AIMS: Although cysteamine was first used in the treatment of cystinosis in 1976 and approved by the FDA as cysteamine bitartrate (Cystagon) in 1994, surprisingly little pharmacological data are available for this compound. Cysteamine and its related drugs are currently being evaluated for the treatment of Huntington's and Parkinson's disease. The aim of te study was to understand the pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. METHOD: Cysteamine bitartrate was delivered through a naso-enteric catheter into the stomach (n = 8), small intestine (n = 8) and caecum (n = 4) of normal subjects. Plasma cysteamine concentrations were determined using LC-MS/MS. RESULTS: The rate and extent of drug absorption were assessed by comparing AUC(0, infinity), C(max) and t(max), among the gastrointestinal infusion sites. Total cysteamine exposure, expressed as area under the curve (AUC(0, infinity)) was greatest when the drug was infused into the small intestine (4331.3 +/- 1907.6 min x microM) followed by stomach (3901.9 +/- 1591.9 min x microM) and caecum (3141.4 +/- 1627.6 min x microM). Cysteamine infusion into the small intestine resulted in the most rapid rise to maximal plasma concentrations (t(max) = 21 +/- 0.56 min); t(max) was delayed to 50 +/- 26 min and 64 +/- 26 min after gastric and caecal infusion, respectively. The maximum cysteamine plasma concentration (C(max)) was reached after infusion of the drug into the small intestine (51 +/- 21 microM), which was higher than plasma C(max) concentrations after gastric (39 +/- 16 microM) and caecal infusion (23 +/- 15 microM). CONCLUSIONS: The pharmacokinetic data generated help extend our understanding of cysteamine.
AIMS: Although cysteamine was first used in the treatment of cystinosis in 1976 and approved by the FDA as cysteamine bitartrate (Cystagon) in 1994, surprisingly little pharmacological data are available for this compound. Cysteamine and its related drugs are currently being evaluated for the treatment of Huntington's and Parkinson's disease. The aim of te study was to understand the pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. METHOD:Cysteamine bitartrate was delivered through a naso-enteric catheter into the stomach (n = 8), small intestine (n = 8) and caecum (n = 4) of normal subjects. Plasma cysteamine concentrations were determined using LC-MS/MS. RESULTS: The rate and extent of drug absorption were assessed by comparing AUC(0, infinity), C(max) and t(max), among the gastrointestinal infusion sites. Total cysteamine exposure, expressed as area under the curve (AUC(0, infinity)) was greatest when the drug was infused into the small intestine (4331.3 +/- 1907.6 min x microM) followed by stomach (3901.9 +/- 1591.9 min x microM) and caecum (3141.4 +/- 1627.6 min x microM). Cysteamine infusion into the small intestine resulted in the most rapid rise to maximal plasma concentrations (t(max) = 21 +/- 0.56 min); t(max) was delayed to 50 +/- 26 min and 64 +/- 26 min after gastric and caecal infusion, respectively. The maximum cysteamine plasma concentration (C(max)) was reached after infusion of the drug into the small intestine (51 +/- 21 microM), which was higher than plasma C(max) concentrations after gastric (39 +/- 16 microM) and caecal infusion (23 +/- 15 microM). CONCLUSIONS: The pharmacokinetic data generated help extend our understanding of cysteamine.
Authors: Ranjan Dohil; Meredith Fidler; Bruce A Barshop; Jon Gangoiti; Reena Deutsch; Michael Martin; Jerry A Schneider Journal: J Pediatr Date: 2006-06 Impact factor: 4.406
Authors: Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian Journal: Proc Natl Acad Sci U S A Date: 2003-02-07 Impact factor: 11.205
Authors: Jonathan H Fox; David S Barber; Bhupinder Singh; Birgit Zucker; Mary K Swindell; Fran Norflus; Rodica Buzescu; Raman Chopra; Robert J Ferrante; Aleksey Kazantsev; Steven M Hersch Journal: J Neurochem Date: 2004-10 Impact factor: 5.372
Authors: N Gretz; F Manz; R Augustin; T M Barrat; C Bender-Götze; M Brandis; H J Bremer; J Brodehl; M Broyer; M Bulla; L Callis; C Chantler; L Diekmann; M J Dillon; F Egli; J H Ehrich; W Endres; A Fanconi; C Feldhoff; J Geisert; D Gekle; B Geschöll-Bauer; K Grote; R Grüttner; W Hagge; C B Haycock; H Hennemann; B Klare; D Leupold; H Löhr; D Michalk; A Oliveira; F Ott; K Pistor; J Rau; K Schärer; F Schindera; H Schmidt; H Schulte-Wissermann; K Verrier-Jones; H P Weber; U Willenbockel; H Wolf Journal: Proc Eur Dial Transplant Assoc Date: 1983
Authors: Daryl M Okamura; Nadia M Bahrami; Shuyu Ren; Katie Pasichnyk; Juliana M Williams; Jon A Gangoiti; Jesus M Lopez-Guisa; Ikuyo Yamaguchi; Bruce A Barshop; Jeremy S Duffield; Allison A Eddy Journal: J Am Soc Nephrol Date: 2013-09-05 Impact factor: 10.121
Authors: Jon A Gangoiti; Meredith Fidler; Betty L Cabrera; Jerry A Schneider; Bruce A Barshop; Ranjan Dohil Journal: Br J Clin Pharmacol Date: 2010-09 Impact factor: 4.335